https://www.selleckchem.com/products/p22077.html
7 16.2 months; hazard ratio [HR] = 0.44; = .01). In the extended Cox models, patients whose tumor burden stayed below the baseline burden throughout therapy had significantly reduced hazards of death (HR = 0.41, = .003, univariate; HR = 0.35, = .02, multivariate). Only one patient (1.1%) experienced pseudoprogression with initial tumor increase and subsequent tumor regression. In patients with advanced non-small-cell lung cancer treated with first-line single-agent pembrolizumab, tumor burden reduction below the baseline burden during th
Like
Comment
Share
